Literature DB >> 11027837

Increased expansion and differentiation of cord blood products using a two-step expansion culture.

I McNiece1, D Kubegov, P Kerzic, E J Shpall, S Gross.   

Abstract

OBJECTIVE: [corrected] The use of allogeneic cord blood (CB) products as a source of cellular support for patients receiving high-dose chemotherapy has been limited primarily to smaller children due to the low numbers of cells in a CB unit. Ex vivo expansion of CB cells has been proposed as a method to increase the number of cells available for transplantation. Following high-dose chemotherapy administration, we transplanted adult patients with CB expanded in static culture for 10 days, in DM containing stem cell factor (SCF), granulocyte colony-stimulating factor (G-CSF), and megakaryocyte growth and development factor (MGDF). Patients achieved neutrophil engraftment in a median of 26 days (range 15 to 45). In an attempt to hasten the time to neutrophil engraftment, we developed a two-step culture system that results in increased expansion of total nucleated cells and further maturation of neutrophil precursors.
MATERIALS AND METHODS: CD34(+) cells isolated from CB products were cultured for 7 days at 37 degrees C in 100-mL Teflon culture bags containing 50 mL of DM containing SCF, G-CSF, and MGDF (100 ng/mL). The cells were harvested from these bags after 7 days of incubation at 37 degrees C and transferred to 1-L Teflon bags containing 1 L of DM plus SCF, G-CSF, and MGDF. After a second culture period of 7 days, the cells were harvested, washed, and assayed for mature (granulocyte-macrophage colony-forming cells [GM-CFC]) and primitive progenitor cells (high proliferative potential colony-forming cells [HPP-CFC]).
RESULTS: The two-step cultures resulted in a median total nucleated cell expansion of 438-fold (range 286 to 952, N = 11); the original one-step cultures resulted in a median expansion of 98-fold (range 59 to 350, N = 5). Equivalent expansion of committed progenitor cells (GM-CFC) and primitive progenitor cells (HPP-CFC) was obtained. CD34(+) cells were expanded a median of 29-fold in the two-step cultures (N = 11). The two-step culture contained more mature neutrophil cells, by morphologic examination, than the one-step cultures, similar to ex vivo expanded peripheral blood progenitor cells (PBPC).
CONCLUSION: The two-step ex vivo expansion conditions described for CB resulted in increased numbers of total nucleated cells, GM-CFC, HPP-CFC, and CD34(+) cells and morphologically resembled ex vivo expanded PBPC, which have been shown to provide more rapid neutrophil engraftment than unexpanded PBPC. We propose that the availability of increased numbers of expanded CB cells may result in more rapid engraftment of neutrophils following infusion to transplant recipients.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11027837     DOI: 10.1016/s0301-472x(00)00520-8

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  22 in total

1.  Delayed immune reconstitution after cord blood transplantation is characterized by impaired thymopoiesis and late memory T-cell skewing.

Authors:  Krishna V Komanduri; Lisa S St John; Marcos de Lima; John McMannis; Steven Rosinski; Ian McNiece; Susan G Bryan; Indreshpal Kaur; Sean Martin; Eric D Wieder; Laura Worth; Laurence J N Cooper; Demetrios Petropoulos; Jeffrey J Molldrem; Richard E Champlin; Elizabeth J Shpall
Journal:  Blood       Date:  2007-08-01       Impact factor: 22.113

Review 2.  Stem cell bioprocessing: fundamentals and principles.

Authors:  Mark R Placzek; I-Ming Chung; Hugo M Macedo; Siti Ismail; Teresa Mortera Blanco; Mayasari Lim; Jae Min Cha; Iliana Fauzi; Yunyi Kang; David C L Yeo; Chi Yip Joan Ma; Julia M Polak; Nicki Panoskaltsis; Athanasios Mantalaris
Journal:  J R Soc Interface       Date:  2009-03-06       Impact factor: 4.118

3.  What is the future for cord blood stem cells?

Authors:  E A de Wynter
Journal:  Cytotechnology       Date:  2003-03       Impact factor: 2.058

Review 4.  Concise review: umbilical cord blood transplantation: past, present, and future.

Authors:  Javier Munoz; Nina Shah; Katayoun Rezvani; Chitra Hosing; Catherine M Bollard; Betul Oran; Amanda Olson; Uday Popat; Jeffrey Molldrem; Ian K McNiece; Elizabeth J Shpall
Journal:  Stem Cells Transl Med       Date:  2014-11-05       Impact factor: 6.940

Review 5.  Engineering cord blood to improve engraftment after cord blood transplant.

Authors:  Rohtesh S Mehta; Hema Dave; Catherine M Bollard; Elizabeth J Shpall
Journal:  Stem Cell Investig       Date:  2017-05-25

6.  CD3(+) and/or CD14(+) depletion from cord blood mononuclear cells before ex vivo expansion culture improves total nucleated cell and CD34(+) cell yields.

Authors:  H Yang; S N Robinson; J Lu; W K Decker; D Xing; D Steiner; S Parmar; N Shah; R E Champlin; M Munsell; A Leen; C Bollard; P J Simmons; E J Shpall
Journal:  Bone Marrow Transplant       Date:  2009-10-19       Impact factor: 5.483

7.  In-vitro Behavior of Human Umbilical Cord Blood Stem Cells Towards Serum Based Minimal Cytokine Growth Conditions.

Authors:  Santwana Mantri; Praksh Chandra Mohapatra
Journal:  Indian J Clin Biochem       Date:  2013-05-29

8.  Cocultivation of umbilical cord blood CD34+ cells with retro-transduced hMSCs leads to effective amplification of long-term culture-initiating cells.

Authors:  Chun-Gang Xie; Jin-Fu Wang; Ying Xiang; Li-Yan Qiu; Bing-Bing Jia; Li-Juan Wang; Guo-Zhong Wang; Guo-Ping Huang
Journal:  World J Gastroenterol       Date:  2006-01-21       Impact factor: 5.742

9.  Ex vivo large-scale generation of human red blood cells from cord blood CD34+ cells by co-culturing with macrophages.

Authors:  Akihito Fujimi; Takuya Matsunaga; Masayoshi Kobune; Yutaka Kawano; Taiko Nagaya; Ikuta Tanaka; Satoshi Iyama; Tsuyoshi Hayashi; Tsutomu Sato; Koji Miyanishi; Tamotsu Sagawa; Yasushi Sato; Rishu Takimoto; Tetsuji Takayama; Junji Kato; Shinsei Gasa; Hiromi Sakai; Eishun Tsuchida; Kenji Ikebuchi; Hirofumi Hamada; Yoshiro Niitsu
Journal:  Int J Hematol       Date:  2008-05       Impact factor: 2.490

Review 10.  Concise review: next-generation cell therapies to prevent infections in neutropenic patients.

Authors:  Marion E G Brunck; Lars K Nielsen
Journal:  Stem Cells Transl Med       Date:  2014-03-05       Impact factor: 6.940

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.